ANLOTINIB ORAL Shows The Potential To Extend PFS And Manageable Adverse Events (AEs) Compared To TOPOTECAN in The SECOND-LINE Setting For Relapsed SMALL CELL LUNG CÁNCER .

ANLOTINIB ORAL Muestra Potencial Para Extender la PFS Versus TOPOTECAN ( Único Tratamiento de Segunda Línea Que Cuenta Con la FULL APPROVAL USFDA ).

Los Eventos Adversos (EA) Son Manejables en Comparación con TOPOTECAN en el Entorno del Tratamiento en SEGUNDA LÍNEA Para el CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS RECIDIVANTE .

THE STUDY INCLUDED 46 SCLC PATIENTS, WITH 20 RECEIVING ANLOTINIB AND 26 RECEIVING TOPOTECAN AS SECOND-LINE TREATMENT .

The ANLOTINIB group showed a significantly longer median PFS compared to the TOPOTECAN group [5.6 vs. 2.2 months; hazard ratio (HR) =0.50; 95% confidence interval (CI): 0.27–0.92; P=0.02]. However, there was no statistically significant difference in OS between the two groups (9.1 vs. 7.7 months; HR =0.88; 95% CI: 0.46–1.70; P=0.71) .

The ORRs were 20.0% and 7.7% (P=0.48), and the DCRs were 70.0% and 23.1% (P=0.007) for the ANLOTINIB and TOPOTECAN groups, respectively .

Treatment-related adverse events (TRAEs) occurred in 13 patients (65.0%) in the ANLOTINIB group and 20 (76.9%) in the TOPOTECAN group (P=0.49) .

Conclusions : 

ANLOTINIB SHOWS THE POTENTIAL TO EXTEND PFS AND MANAGEABLE ADVERSE EVENTS (AEs) COMPARED TO TOPOTECAN IN THE SECOND-LINE SETTING for RELAPSED SMALL CELL LUNG CÁNCER .